Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.

Jessup JM, Stewart A, Greene FL, Minsky BD.

JAMA. 2005 Dec 7;294(21):2703-11.

PMID:
16333005
2.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group.

J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12.

4.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x. Epub 2009 Jun 25.

PMID:
19563521
5.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

PMID:
15067028
6.

Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.

Morris M, Platell C, McCaul K, Millward M, van Hazel G, Bayliss E, Trotter J, Ransom D, Iacopetta B.

Int J Colorectal Dis. 2007 Aug;22(8):887-95. Epub 2007 Jan 19.

PMID:
17235506
7.

Adjuvant therapy for colon cancer in the new millenium.

Rao S, Cunningham D.

Scand J Surg. 2003;92(1):57-64. Review.

PMID:
12705552
8.

Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.

Bergquist JR, Thiels CA, Spindler BA, Shubert CR, Hayman AV, Kelley SR, Larson DW, Habermann EB, Pemberton JH, Mathis KL.

Dis Colon Rectum. 2016 Dec;59(12):1142-1149.

PMID:
27824699
9.

Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.

Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.

Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

PMID:
23204187
10.

Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.

Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, Hanna N, Pandya N, Mullins CD.

Med Care. 2009 Dec;47(12):1229-36. doi: 10.1097/MLR.0b013e3181b58a85.

PMID:
19786906
11.

Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?

Van Cutsem E, Costa F.

JAMA. 2005 Dec 7;294(21):2758-60. No abstract available.

PMID:
16333012
12.

Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.

Figueredo A, Fine S, Maroun J, Walker-Dilks C, Wong S.

Cancer Prev Control. 1997 Oct;1(4):304-19. Erratum in: Cancer Prev Control 1997 Dec;1(5):351.

PMID:
9765754
13.

Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.

Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM; Norwegian Gastrointestinal Cancer Group.

Acta Oncol. 2009;48(3):368-76. doi: 10.1080/02841860902755244.

PMID:
19242829
14.

Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.

Focan C, Bury J, Beauduin M, Herman ML, Vindevoghel A, Lecomte M, Brohée D, Canon JL, Focan-Henrard D; GRECCR Belgium.

Anticancer Res. 2000 Nov-Dec;20(6C):4665-72.

PMID:
11205198
15.

Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused.

Becerra AZ, Probst CP, Tejani MA, Aquina CT, González MG, Hensley BJ, Noyes K, Monson JR, Fleming FJ.

Surgery. 2015 Sep;158(3):692-9. doi: 10.1016/j.surg.2015.03.057. Epub 2015 May 29.

PMID:
26032822
16.

North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.

O'Connell MJ.

Semin Oncol. 2001 Feb;28(1 Suppl 1):4-8.

PMID:
11273589
17.

Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.

Hsieh MC, Chiu YW, Velasco C, Wu XC, O'Flarity MB, Chen VW.

J Registry Manag. 2013 Winter;40(4):180-7.

PMID:
24625772
18.

Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.

Yun HR, Kim HC, Yun SH, Lee WY.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2466-71. doi: 10.5754/hge10260.

PMID:
23169179
20.

[Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study].

Mondaca S, Villalón C, Leal JL, Zúñiga Á, Bellolio F, Padilla O, Palma S, Garrido M, Nervi B.

Rev Med Chil. 2016 Feb;144(2):145-51. doi: 10.4067/S0034-98872016000200001. Spanish.

Supplemental Content

Support Center